Reprogramming the Immune System with Metabolites
Computational Biology for Disease Discovery
Unlike traditional genomics approaches that target single data types, Nexus™ integrates genomics, proteomics, metabolomics, and microbiome data to discover immunometabolic intervention points.
Our multi-omics platform identifies metabolites that reprogram immune function across diseases - transforming therapeutic discovery from years and billions to weeks and thousands. We already have a 68-asset pipeline, two FDA designation approvals, and active licensing negotiations.
Validated Predictive Accuracy
Double-blind validation results demonstrate consistent high-accuracy predictions across multiple disease indications. Our confidence in efficacy and safety stems from discovering these targets already working safely in humans through observational studies and retrospective analysis of existing therapeutics.
Statistical Validation
Examples of double-blind validation & test in confusion matrices
Necrotizing Enterocolitis (NEC)
Propionic Aciduria (PA)
Citrullinemia Type 1 (CTLN1)
Systemic Juvenile Arthritis (sJIA)
From Single Assets to System-Wide Solutions
Nexus™: First platform to systematically reprogram immunity across thousands of diseases
We own the infrastructure that makes biology programmable
Available Therapeutic & Diagnostic Assets by Disease
68 therapeutic and diagnostic assets across 7 major disease categories
Therapeutic & Diagnostic Assets
Real-time development status across disease categories
Platform Summary
68 therapeutic assets discovered across 7 major disease categories with 2 FDA rare pediatric disease designations approved